预约演示

更新于：2026-09-01

Ipilimumab

伊匹木单抗

更新于：2026-09-01

概要

基本信息

药物类型

单克隆抗体

别名

Anti CTLA-4 monoclonal antibody、Anti-CTLA-4 Mab、Ipilimumab (Genetical Recombination)

+ [17]

靶点

CTLA4

作用方式

抑制剂

作用机制

CTLA4抑制剂(细胞毒性T淋巴细胞相关抗原4抑制剂)

治疗领域

肿瘤消化系统疾病呼吸系统疾病+ [11]

在研适应症

微卫星高度不稳定性直肠癌PD-L1阳性非小细胞肺癌转移性肝细胞癌+ [265]

非在研适应症

急性双系白血病急性双表型白血病复发性急性淋巴细胞白血病+ [154]

原研机构

Bristol Myers Squibb Co.

在研机构

National Cancer Institute

Bristol Myers Squibb Co.

The University of Texas MD Anderson Cancer Center

+ [17]

非在研机构

National Institutes of Health Clinical Center

Checkmate Pharmaceuticals, Inc.

University of Southern California

+ [11]

权益机构

Nektar Therapeutics

Inspirna, Inc.

Nexoplex Bio, Inc.

+ [8]

最高研发阶段批准上市

首次获批日期

美国 (2011-03-25),

黑色素瘤

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (日本)、孤儿药 (韩国)、突破性疗法 (中国)、优先审评 (澳大利亚)、优先审评 (美国)、附条件批准 (中国)、优先审评 (中国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

Sequence Code 143797L

来源: *****

Sequence Code 9060585H

来源: *****

关联

918

项与伊匹木单抗相关的临床试验

NCT07587827

/ Not yet recruiting临床1期IIT

A Phase 1, Open-label, Dose-escalation and Dose-expansion Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer

This is a phase 1, open-label, multicentric study evaluating the safety, feasibility and efficacy of ODI-2001, a personnalized therapeutic cancer vaccine composed of DNA neoantigen vaccine, Modified Vaccinia virus Ankara (MVA) viral adjuvant and anti-CTLA4 (ipilimumab), in patients with metastatic or locally advanced colorectal or pancreatic cancer. The study includes a dose-escalation phase to determine the maximum tolerated dose (MTD) followed by an expansion phase to evaluate efficacy in terms of progression-free survival

开始日期2026-11-01

申办/合作机构

Centre Georges François Leclerc

NCT07770100

/ Not yet recruiting临床2期IIT

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

This is a Phase II clinical study for people with stage IV cancer. The study will evaluate the use of stereotactic body radiation therapy (SBRT), a type of focused radiation treatment, together with immunotherapy-based treatment. SRBT will be used to treat multiple areas of cancer that have spread to other parts of the body. The study will evaluate whether this treatment approach can be safely given while patients continue their planned cancer treatment and may help control their cancer.

开始日期2026-10-01

申办/合作机构

University of Kentucky

NCT07762716

/ Not yet recruiting临床1/2期

Phase 1/2 Trial of a Combination Immunotherapy Treatment for Solid Tumors Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

The objective of this study is to evaluate the safety, feasibility, and preliminary antitumor activity of this multi-component immunotherapy strategy in patients with advanced solid tumors. The study is designed to assess whether coordinated enhancement of antigen-specific T-cell priming and tumor microenvironment modulation can improve immune-mediated tumor control.
In this study, BreakVax with adjuvants (Montanide and Poly-ICLC) is administered in combination with:
1. Low-dose subcutaneous ipilimumab at the injection site as a dendritic cell adjuvant to enhance local dendritic cell-mediated T-cell priming;
2. Pembrolizumab to mitigate PD-1-mediated T-cell exhaustion and sustain effector function;
3. Standard-of-care chemotherapy, which may promote immunogenic cell death, increase antigen release and modulate the tumor microenvironment; and
4. Losartan and aspirin, which have been associated in preclinical and translational studies with modulation of stromal architecture, vascular normalization, and reduction of tumor-associated immunosuppressive signaling.
This is a Phase 1/2, multi-center, open-label single-arm clinical study in adult patients who have Glioblastoma (GBM).
The study consists of two components: a Safety Lead-in Cohort and a combination therapy cohort. The Safety Lead-in Cohort is designed to evaluate safety and tolerability of the study combination and to characterize dose-limiting toxicities (DLTs). The combination therapy cohort portion intends to evaluate the superiority of the study combination treatment vs the SOC chemotherapy, measured by OS at 12 months

开始日期2026-09-01

申办/合作机构

BreakBio Corp

[+1]

100 项与伊匹木单抗相关的临床结果

登录后查看更多信息

100 项与伊匹木单抗相关的转化医学

登录后查看更多信息

100 项与伊匹木单抗相关的专利（医药）

登录后查看更多信息

5,509

项与伊匹木单抗相关的文献（医药）

2026-12-31·CNS oncology

Tailored management of a melanoma patient with bleeding brain metastases and deep vein thrombosis with thrombectomy

Article

作者: Ceccarelli, Corrado ; Pastina, Ilaria ; Del Roscio, Davide ; Viterbo, Antonella ; De Angelis, Filippo ; Pieraccini, Massimo ; Arezzini, Luca

CASE PRESENTATION:

We describe a 62-year-old man with disseminated melanoma (initially staged pT2aN0M0, AJCC stage IB, 8th edition AJCC) who developed multiple brain metastases with hemorrhagic transformation, pulmonary embolism, retrobulbar progression with eyeball herniation, and deep vein thrombosis (DVT). After cerebral edema improved with corticosteroid tapering and the patient became asymptomatic, he started combination immunotherapy with ipilimumab (3 mg/kg q3w × 4) and nivolumab (1 mg/kg q3w × 4). Despite initial benefit, progression led to radiotherapy for retrobulbar lesion and subsequent targeted therapy with encorafenib (450 mg daily) and binimetinib (45 mg twice daily). Shortly after, the patient developed symptomatic left-leg DVT extending to the femoral vein with segmental pulmonary embolism. Given the contraindication to full anticoagulation, mechanical thrombectomy with the Indigo Aspiration System was performed, followed by prophylactic LMWH at reduced therapeutic dose (enoxaparin 1 mg/kg once daily due to recent thrombectomy and hemorrhagic risk from bleeding brain metastases). During targeted therapy, the patient experienced partial regression of brain, liver, and peritoneal metastases, although intracranial hemorrhage recurred later.

CONCLUSIONS:

This case highlights the value of a multidisciplinary, tailored approach integrating immunotherapy, radiotherapy, targeted therapy, and mechanical thrombectomy with no DVT recurrence observed following thrombectomy at 6-month follow-up.

2026-12-01·JOURNAL OF BIOMOLECULAR NMR

A fast and efficient strategy for the NMR assignment of Fab methyl groups

Article

作者: Henot, Faustine ; Doyen, Camille ; Frances, Oriane ; Güntert, Peter ; Vibert, Béatrice ; Crublet, Elodie ; Giraud, Arthur ; Dbira, Sarra ; Favier, Adrien ; Imbert, Lionel ; Boisbouvier, Jérôme ; Clavier, Séverine

Owing to their high specificity and therapeutic effectiveness, monoclonal antibodies (mAbs) have rapidly become one of the leading classes of biologic drugs used to treat critical illnesses. The antigen-binding fragment (Fab) of mAbs plays a key role in the antigen recognition, so its structural characterization is essential, as even a slight change to its Higher Order Structure (HOS) can impact the antibody's potency. Recently, 2D methyl NMR has been introduced as a powerful method to assess both the structure and integrity of therapeutic Fab fragments. However, the identification of methyl group resonances in NMR spectra remains rare since Fabs are large heterodimers of ~ 50 kDa. Here, we present the methyl group assignment of an IgG1 Fab produced in a cell-free system with an optimal isotope labelling. We first assigned 99% of the alanine, isoleucine, leucine, methionine, and valine methyl groups of the therapeutic Fab targeting LAMP1 antigen. Building on this assignment, we propose a "divide and conquer" strategy that exploits sequence identities to rapidly assign methyl groups of other IgG1 Fabs. We demonstrate that the assignment of the Fab's constant region can easily be transferred from one IgG1 to another and that the variable part of a new Fab can be assigned using smaller uniformly ¹⁵N,¹³C-labelled constructs. We applied our strategy to ipilimumab's Fab and, using the assignment of ipilimumab's variable part and Fab anti-LAMP1's constant part, we could transfer the assignment of 89% of the methyl-containing amino acids to the entire ipilimumab Fab without having to produce deuterated samples. This assignment strategy can be generalised to any other IgG1 Fabs provided that their constant regions are identical and the strategy can be adapted to accommodate the expression levels of the different variable domains. This new method drastically facilitates the Fab assignment process, making it suitable for the pharmaceutical timeline.

2026-09-01·AMERICAN JOURNAL OF OPHTHALMOLOGY

Immune Checkpoint Inhibitor–Associated Uveitis: Insights From Comparative Analyses Across Malignancies and Drug Classes

Article

作者: Mizuno, Yuka ; Hassan, Khaled A ; Kennedy, Lucy B ; Barbosa, Gabriel Castilho S ; Mohan, Nitesh ; Kaelber, David C ; Bellanda, Victor ; Srivastava, Sunil K ; Schulgit, Matthew J ; Sharma, Sumit

PURPOSE:

Understanding how the risk of immune checkpoint inhibitor (ICI)-associated noninfectious uveitis (NIU) differs by malignancy and drug class may help understand its pathophysiology and guide targeted ophthalmic surveillance. This study aims to evaluate the comparative risk of ICI-associated NIU across different malignancies and drug classes.

DESIGN:

Retrospective, multicenter clinical cohort study.

SUBJECTS:

Adults with metastatic melanoma, lung cancer, renal cell carcinoma (RCC), urothelial carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, or nonmelanoma skin cancer. Propensity score matching was performed for demographics, comorbidities, and socioeconomic factors.

EXPOSURES:

Prescription of an ICI agent of any class (anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA-4]).

MAIN OUTCOME MEASURES:

The primary outcome was new-onset NIU within 24 months of first ICI prescription. Relative risks (RR) with 95% confidence intervals (CIs) were calculated. Subgroup analyses compared outcomes across malignancies, with and without ipilimumab or nivolumab exposure, and between ICI subclasses when used in monotherapy.

RESULTS:

After matching, 16,834 patients with melanoma and 16,834 with lung cancer were included. Melanoma patients had a higher risk of NIU compared with lung cancer (1.10% vs 0.18%; RR, 6.17; 95% CI, 4.20-9.08). Excluding ipilimumab/nivolumab, melanoma remained associated with increased risk (0.53% vs 0.16%; RR, 3.40; 95% CI, 1.68-6.88). Across malignancies, melanoma consistently demonstrated elevated risk relative to other cohorts. Lung cancer showed borderline decreased risk compared to RCC (0.19% vs 0.36%; RR, 0.53; 95% CI, 0.31-0.90), but this effect was not significant after excluding ipilimumab/nivolumab. In drug-class analyses, anti-PD-1 agents did not demonstrate a significantly different risk of NIU compared with anti-PD-L1 agents (0.26% vs 0.20%; RR, 1.33; 95% CI, 0.89-1.99). Anti-cytotoxic T-lymphocyte-associated protein 4 agents could not be compared due to limited use as monotherapy.

CONCLUSIONS:

Both malignancy type and ICI subclass influence the risk of ICI-associated uveitis. Melanoma carries an intrinsically higher risk independent of ipilimumab/nivolumab exposure, whereas RCC's risk appears largely ipilimumab/nivolumab-driven. These findings underscore the need for careful monitoring of melanoma patients initiating ICIs and suggest that the pathophysiology of ICI-related uveitis is driven by both drug- and disease-specific factors.

2,327

项与伊匹木单抗相关的新闻（医药）

2026-09-01

·今日头条

各类癌症成功实现完全缓解！新一代癌症疫苗让5名患者肿瘤清零!

5 个人，5 种癌，全部成功实现完全缓解！这不是虚构，而是刚刚发表在国际权威期刊医学病例报告里，白纸黑字写下的真实结局--一群被医生判为"无牌可打"的晚期转移患者，在接受了同一种全新的双负载自体树突状细胞（DC）疗法后，影像学（PET/CT 或组织活检）证实： 5人全部达到完全缓解，且缓解持续了 6 到 28 个月，没有出现一例 3 级及以上严重副作用。对很多晚期实体瘤患者来说，最绝望的从来不是"确诊"，而是"确诊之后所有标准治疗都试过了，肿瘤还在长"。化疗、靶向、免疫检查点抑制剂，一旦陆续耐药，医生能开的牌就越来越少。医学界一直在找一种既能"量身定制"、又符合人体自身逻辑的办法。近期，一则重磅临床研究打破了这个死亡定论！国际权威研究公布一组振奋人心的案例： 5名穷尽手术、放疗、化疗、靶向、PD-1免疫治疗的晚期绝症患者，全部病情进展、全线耐药、濒临绝境，在接受新一代双负载DC树突细胞免疫疗法（IDCT）后， 100%实现影像学完全缓解！肿瘤彻底清零！最长无癌生存已达28个月！靠自身免疫系统重启绝杀癌细胞，让无数晚期、耐药、无药可医的实体瘤患者，重新抓住生的希望！各类癌症成功实现完全缓解！新一代DC疫苗让5名患者肿瘤清零，最长缓解28个月！本次国际多中心联合研究，突破性创新双抗原负载DC技术，打破传统免疫治疗局限。也是目前为数不多，可同时攻克 PD-1耐药、肿瘤免疫冷微环境、术后残留复发三大难题的个体化细胞疗法，为穷尽所有治疗手段的晚期实体瘤患者，开辟了全新的长效治愈赛道，对整个实体瘤免疫治疗领域有着里程碑式的革新意义。 01 前列腺癌多发转移、多次复发！最终病灶全部消退 62岁的高龄前列腺癌患者，曾为抗癌拼尽全力。确诊后他第一时间接受机器人根治手术、扩大淋巴结清扫，术后又坚持质子放疗、长达18个月的内分泌药物治疗，本以为能稳住病情。可癌症的凶险远超想象！治疗结束后短短数月，病情快速反扑，直接发展为去势抵抗性前列腺癌，癌细胞疯狂扩散，侵袭直肠、纵隔、胸腹淋巴结、胸骨，全身多处出现转移灶。为了控瘤，患者先后尝试激光、冷冻、电穿孔等多种局部消融手术，一次次打掉转移病灶，可癌细胞依旧死灰复燃。肿瘤指标持续飙升， PSA从正常值暴涨至140ng/mL ，循环肿瘤细胞持续升高，全身多发转移灶在PET-CT上清晰可见，病情彻底失控。走投无路之下，他选择尝试新一代双负载DC免疫疗法。仅仅完成 3次定制DC疫苗淋巴靶向注射后，奇迹悄然发生：肿瘤指标断崖式下跌，PSA从140ng/mL暴跌至0.6ng/mL！后续复查PSMA-PET/CT，全身所有转移病灶几乎完全消退，仅残留极少量纤维化组织，无任何活跃癌细胞。治疗过程全程温和，仅出现轻微背痛、短暂肌肉酸痛，没有脱发、呕吐、骨髓抑制等任何重度副作用。如今患者持续保持完全缓解状态，无复发、无进展，摆脱绝症威胁！ 02 PD-1耐药晚期黑色素瘤患者重获新生 39岁的年轻患者，本该正值壮年，却不幸确诊转移性恶性黑色素瘤。癌细胞突破皮肤屏障，疯狂转移至肺部、纵隔淋巴结，肺部长出4.7cm的巨大肿瘤，伴随多发卫星结节，胸闷、喘息、呼吸困难，严重影响正常生活。临床上针对黑色素瘤的王牌方案——双免疫联合治疗（伊匹木单抗+纳武利尤单抗），他第一时间用上。可命运依旧残酷，仅仅治疗4周，患者就出现原发性PD-1耐药，治疗失效。肿瘤快速进展，肺部肿块持续增大29%，飙升至5.8cm，全身淋巴结进一步肿大，患者身体状态急剧崩塌，生命进入倒计时。就在所有医生都束手无策的时候，他加入DC免疫治疗项目，接受个体化双负载DC疫苗靶向治疗。 27个月长期随访复查CT，原本4.7cm的肺部巨瘤彻底萎缩纤维化，所有转移淋巴结钙化消退，多次活检未发现任何存活癌细胞。如今患者完全回归正常生活，运动、工作不受限制！ 03 术后反复复发！唇颌部肿瘤侵袭骨膜，耐药黑色素瘤28个月无癌 33岁的年轻患者，确诊恶性程度极高的促纤维增生性黑色素瘤，伴随神经侵犯、高分裂活性，复发风险极高。确诊后他立刻接受全切手术、淋巴结清扫、皮瓣重建，手术做得干净彻底。为了防复发，术后他坚持使用PD-1抑制剂辅助治疗，万万没想到，最凶险的复发还是如期而至。治疗期间肿瘤快速复发，侵袭整个唇部重建组织，进一步侵犯下颌骨骨膜、颈部淋巴结，形成 5.5cm的巨大恶性肿块。绝境之中，患者接受双负载DC个体化疫苗治疗，精准靶向淋巴结病灶注射特训后的免疫细胞。疗效堪称惊艳！治疗 5个月，巨大肿瘤大幅缩小，颈部转移淋巴结完全消退；治疗18个月，患者彻底停药，体能、容貌、生活状态完全恢复如初。截至目前，患者已持续28个月无疾病证据（NED），影像学复查零病灶、零复发，成为晚期耐药黑色素瘤长生存的标杆案例！ 04 高侵袭三阴性乳腺癌终获完全缓解 58岁女性患者，不幸确诊预后最差的三阴性乳腺癌，先后完成蒽环+紫杉类联合化疗、乳房切除术、腋窝淋巴结清扫，后续又追加辅助放疗、铂类挽救化疗，用尽所有主流治疗手段。即便层层设防，癌症依旧强势复发！术后短短两年，癌细胞侵袭腋窝、胸大肌、颈部淋巴结，全身炎症指标、肿瘤负荷指标全面飙升，身体免疫彻底紊乱，成为典型的免疫冷肿瘤，对常规治疗完全不敏感。面对这例多次治疗、多次复发的难治三阴乳腺癌，医生已无标准方案可续。抱着最后一丝希望，患者接受新一代DC免疫疫苗治疗。个体化定制的双负载DC细胞，成功唤醒沉睡的免疫系统，精准击杀全身残留癌细胞。治疗后各项异常炎症、肿瘤指标全部恢复正常，身体免疫功能彻底重塑。随访至治疗满12个月， PET-CT全身复查阴性，所有转移病灶完全消失，达到临床完全缓解！如今患者体能状态满分，生活质量极佳，无需任何放化疗维持，摆脱三阴乳腺癌的复发魔咒！ 05 双重绝症叠加！晚期膀胱癌+多发性骨髓瘤成功清零这是本次研究中最凶险、最让人揪心的一例超级疑难病例！62岁患者同时确诊两种恶性肿瘤：高级别浸润性尿路上皮癌（膀胱癌）+多发性骨髓瘤。患者此前因骨髓瘤接受自体干细胞移植，长期靶向药物维持治疗，本就免疫功能极度薄弱。雪上加霜的是，膀胱癌快速进展，癌细胞突破膀胱，全身侵袭转移，出现肺门淋巴结转移、恶性胸腔积液、胸膜广泛侵犯。在接受无创、温和的DC免疫疫苗治疗后，创造了医学奇迹！三次靶向淋巴结注射治疗后，患者胸闷、呼吸困难症状彻底消失。复查影像显示：恶性胸腔积液完全吸收，胸膜病灶消退，肺门转移淋巴结大幅缩小至正常范围。 18个月长期随访，患者持续完全缓解，膀胱镜、CT复查零病灶，身体各项指标全面恢复正常，彻底告别卧床、吸氧，完全回归正常生活！激活自身免疫系统攻击癌症！揭秘树突细胞强大的抗癌力看完5组案例，很多患者疑惑：放化疗、PD-1都无效，为什么DC疫苗能清零晚期肿瘤？通俗来讲，树突状细胞（DC）是人体免疫系统的“超级侦察兵”。晚期耐药肿瘤大多是“免疫冷肿瘤”，癌细胞会伪装自己、麻痹免疫细胞，让免疫系统“看不见、打不着”，这也是所有药物耐药的核心根源。而本次突破的新一代双负载DC免疫疗法，和普通DC疗法完全不同：它提取患者自身肿瘤专属抗原，通过肿瘤mRNA+肿瘤裂解物双重加载技术，全方位教会免疫细胞识别患者独有的癌细胞特征，再将特训后的成熟免疫细胞回输体内，精准唤醒全身免疫大军。既能逆转PD-1耐药、激活冷肿瘤，又能生成长期免疫记忆，杀除残留微小癌细胞，从根源杜绝复发转移！全程用自身细胞抗癌，无耐药、无重度副作用，适配各类晚期、耐药、体弱患者。目前树突状细胞肿瘤疫苗正在全球范围内被迅速、广泛的研究 ,并且已在动物实验和早期的临床实验中取得了很有意义的结果，其中，脑瘤，肾癌，黑色素瘤的树突细胞疫苗研发已进入三期临床试验阶段，有望上市。还有一些国家的树突细胞疫苗已经正式进入临床应用，一些早期肿瘤患者可以在手术后考虑使用疫苗联合放化疗辅助治疗，起到杀伤残余癌细胞，产生免疫记忆，预防癌症复发和转移。大家可以提交病历至全球肿瘤医生网医学部评估申请(4006667998). 此外，全球在研的抗癌疫苗临床试验有200多项。科学家们说。“如果成功，在随后的试验中，个体化疫苗将被用于各类癌症，拥有足够数量的新抗原接种疫苗具有巨大潜力。 5例绝境翻盘的抗癌奇迹，再次证明：晚期不等于终末期，耐药不等于无药可救。在精准免疫治疗时代，只要不放弃，每一位肿瘤患者，都有收获长期生存、临床治愈的机会！本文为全球肿瘤医生网原创，未经授权严禁转载

2026-08-31

·网易号

肿瘤免疫治疗性抗体临床药理学介绍｜免疫复杂性读书会第19期

导语免疫检查点抑制剂（ICIs）开启了肿瘤免疫治疗的普及时代，使得晚期癌症获得了长期控制的机会。在ICIs出现之前，不可手术的晚期实体瘤极难获得长期无瘤生存。以不可手术的晚期实体瘤的5年生存率统计，非小细胞肺癌从低于4%提高到20%以上；肾癌从低于14%提高到25%以上；黑色素瘤从低于10%提高到43%以上。如何继续提高肿瘤免疫治疗效果，对原有抗体做工程优化是一个重要手段和方向。本期读书会为免疫复杂性读书会第19期，中山大学附属肿瘤医院李苏教授将在本期解读肿瘤免疫治疗抗体药物的药理作用机制，以助力临床肿瘤免疫治疗优化方案设计。集智俱乐部联合广州市荔湾中心医院秦健勇医生、四川大学生物医学工程学院敖平教授、天津工业大学数学科学学院雷锦志教授、中山大学附属肿瘤医院张晓实教授以及中国科技大学生命科学院博士生秦晓玉共同发起，以免疫学为具体场景，以复杂科学为方法论，试图整合范式转型与理论构建、机制研究与数理建模、药物研发和临床实践以肿瘤免疫治疗为核心问题探讨21世纪生命科学认知范式转型的关键细节。自2026年4月13日启动，每周一晚19：30-21：30进行，持续时间预计26周。欢迎对肿瘤免疫学、系统生物学、复杂网络与数学生物学交叉领域感兴趣的朋友加入！报告简介从药物作用机制角度系统介绍了双特异性抗体（双抗）的药理机制与临床应用。双抗可同时结合两个不同抗原或同一抗原的两个表位，主要分为免疫细胞定位类、免疫细胞激活类和信号通路阻断类三大类型。文章以卡度尼利单抗（PD-1/CTLA-4双抗）和依沃西单抗（PD-1/VEGF双抗）为代表，剖析了双抗在克服耐药、增强亲和力方面的优势，也直面了共用Fc段导致的毒性、免疫原性及半衰期限制等挑战。进而引出艾托组合抗体（QL1706）通过2:1固定比例、不同IgG亚型和差异半衰期的创新设计，实现疗效与安全性的平衡。最后展望了三抗、四抗等多特异性抗体的发展趋势，指出多靶点抗体是突破肿瘤异质性和免疫单药局限的重要方向。分享大纲一、双抗的药理学基础定义：一个抗体分子结合两个不同抗原或同一抗原的两个表位，全球已批准15款三大作用类型：聚集/定位免疫细胞类（如CD3×CD19）激活免疫细胞类（"踩油门"OX40/4-1BB等，"去刹车"PD-1/CTLA-4等）阻断肿瘤发展相关信号相比单抗的优势：克服耐药、增强结合强度与特异性、减少脱靶固有局限：重轻链错配风险、免疫原性增加、共用Fc段导致药理冲突二、代表性PD-1/CTLA-4双抗：卡度尼利单抗结构：四价IgG1双抗，PD-1结合域来自派安普利单抗，CTLA-4结合域以scFv经Gly4Ser接头融合至重链C端机制特点：双靶点同时存在时解离速率慢5.95倍，亲和力显著提升临床数据：宫颈癌ORR=32%，3-4级不良事件约30%核心问题：共用Fc段无法实现亚型优选；半衰期短，需每2周给药三、PD-1/VEGF双抗：依沃西单抗结构：Tetrabody技术构建的四价双抗协同效应：与VEGF-A形成复合物后，对PD-1的亲和力提升18倍以上生物学活性：抗PD-1活性与派安普利相当，抗VEGF活性与贝伐珠单抗相当四、下一代方案：艾托组合抗体（QL1706）本质：PD-1单抗（艾帕洛利，IgG4）+ CTLA-4单抗（托沃瑞利，IgG1 R255K突变）按2:1固定比例组合三大创新：亚型灵活：PD-1用IgG4（无ADCC，保留效应T细胞）；CTLA-4用IgG1（有ADCC，清除Treg）半衰期差异化：CTLA-4单抗经R255K改造后半衰期缩至约1周，降低毒性暴露同步给药：5mg/kg Q3W，两种单抗同步入血但各自独立药代对比优势：克服双抗共用Fc段的骨架不可优选、半衰期不可调的缺陷五、多抗的未来发展三抗代表：HPN217（CD3/BCMA/HAS）、SAR442257（CD3/CD28/CD38）等进入临床四抗代表：百利药业GNC系列（PD-L1/CD3/4-1BB/ROR1等）核心价值：在免疫细胞桥接、激活、信号阻断三大机制中多重组合，应对肿瘤异质性核心概念双特异性抗体（BsAb）：单分子同时靶向两个抗原或表位的工程化抗体，结构灵活，可通过四价、三价或组合形式实现免疫细胞桥接、共刺激或信号阻断，已广泛用于肿瘤免疫治疗。T细胞重定向：通过CD3×肿瘤抗原双抗将T细胞物理桥接至肿瘤细胞，绕过TCR特异性直接激活杀伤，代表药物如Blinatumomab，优势为起效快，但易引发细胞因子释放综合征。共用Fc段限制：双抗两个靶点共享同一Fc，导致半衰期一致、亚型不可独立优化，难以兼顾安全性与药效，且重轻链错配风险高，增加生产工艺难度与免疫原性风险。解离速率（Koff）：卡度尼利单抗在双靶点共存时Koff降低5.95倍，结合更稳固，但也导致免疫毒性升高，体现双抗亲和力与安全性之间的平衡挑战，是药效评估关键参数。菊花链式串联：依沃西单抗与VEGF-A形成复合物后进一步增强PD-1结合，协同阻断免疫抑制与血管生成，体现双抗多价协同效应，为联合治疗提供新思路。MabPair平台：齐鲁制药技术，可稳定生产固定比例双单抗组合，无错配，实现亚型与半衰期差异化设计，克服传统双抗Fc段限制，提升疗效与安全窗。R255K突变：降低CTLA-4单抗与FcRn亲和力，半衰期缩至约1周，减少毒性暴露，提升安全窗，是艾托组合抗体实现PD-1/CTLA-4协同阻断的关键工程化改造。多抗（三抗/四抗）：在双抗基础上增加第三或第四靶点，实现免疫细胞桥接、共刺激与信号阻断多重组合，应对肿瘤异质性与免疫逃逸，代表下一代肿瘤免疫疗法。主讲人介绍主讲人：李苏，中山大学附属肿瘤医院临床研究部/机构办公室主任，专长：肿瘤药理。学术任职：国家食药监督管理局“药物临床试验机构”资格认定检查和复核检查专家；广东药学会理事，中国药学会理事；广东省药学会药物临床试验专委会常委；广东省药理学会药物代谢专委会常委；中国药理学会治疗药物监测研究专业委员会常委；广东省药理学会治疗药物监测研究专业委员会常委；广东省精准应用学会CRO产业链分会主委。主要研究方向：抗癌药物的I期临床试验和抗癌药物的临床药理工作。精通抗肿瘤药物药理学和临床药理学的基本理论、专业知识和技术，对抗癌药物的Ⅰ期临床试验的设计、实施、总结以及抗癌药物的临床药理，在临床应用形成独特的优势，同时协助解决抗癌药物剂量浓度及药效之间的关系，以及药物与药物之间的相互作用与临床药理问题和最新的抗肿瘤药物的个体化给药。熟悉药物体内的分析理论和技术，能熟练操作质子吸收光谱仪、高效液相色谱仪、色谱-质谱联用仪、酶标仪等分析设备。主持多项I期临床药代动力学研究课题：如TQB3525,TQB3139, SM-1, TQB3728, PEP06，DX1002，LH031，Hemey020，ACC006，PEG-SN38，苯达莫司汀，KH903，PEG-恩度，甲磺酸普喹替尼，康普立停，rh-Trail等，并发表60多篇相关文章；开展氨甲喋呤、5-氟尿嘧啶、二氢尿嘧啶脱氢酶、HVA/VMA、舒尼替尼、伊马替尼、帕唑帕尼等的多种抗肿瘤药物临床监测，并发表了多篇相关的文章。开展药物基因多态性与抗癌药物的疗效和毒性的关系；开展了口腔肿瘤发生、发展、转移机制的研究。参考文献Paul S, Konig MF, Pardoll DM, et al. Cancer therapy with antibodies. Nat Rev Cancer. 2024;24(6):399-426. doi:10.1038/s41568-024-00690-x.Goebeler M E, Stuhler G, Bargou R. Bispecific and multispecific antibodies in oncology: opportunities and challenges[J]. Nature Reviews Clinical Oncology, 2024, 21(7): 539-560.Hidalgo-Filho C M, Santo V, Gariazzo E, et al. Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies[J]. Journal of Clinical Oncology, 2026, 44(19): 1833-1844.Wolchok J D, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma[J]. The New England journal of medicine, 2024, 392(1): 11.读书会在做什么免疫复杂性读书会，从2026年4月13日开始，每周一晚19：30，连续半年，聚焦免疫复杂性主题。读书会主题划分为三个模块：【导言】生命科学范式漫谈由资深生命科学研究者朱景德教授激情畅谈复杂系统范式对于生命科学研究的意义。【机制解读篇】由中国学者敖平教授介绍基于普适的达尔文演化力学这个第一性原理发展起来内源性网络理论在理解复杂生命现象中的应用；这部分的整体架构是以EVO-DEV-ECO框架展开的，邀请国内研究免疫机制演化和发育的顶尖团队，分享他们的研究成果。同时对免疫机制的核心问题如免疫代谢、T细胞功能调控网络、神经-免疫的对话由长期关注此问题的资深学者展开探讨。范式转换需以方法论为基础，由在此领域深耕的青年才俊介绍干湿结合的生物学机制研究方法，免疫稳态与免疫韧性是免疫健康的主旋律，我们也尝试基于复杂科学视角尝试对其进行解读……【数理建模篇】数学本质上是一种对认知进行准确描述和具有很强逻辑性的语言，由通用的数学符号体系建立起来的数学语言作为科学基础的工具为人类深化对自然界的认知起了不可或缺的作用，数学在不断演化中发展，同时不断拓展着人类的认知边疆。不少物理学家都曾感叹数学不可思议的有效性，数学，尤其是对称性思想在构建物理学宏伟大厦的过程中是不可缺少的工具。数学在科学发展史上的巨大作用，使得科学家们又尝试以数学工具介入对生命现象的探索，但又难免惆怅：喟叹其不可思议的无效性。癌生物学家 Robert Weinberg 提出“数学能否帮助人们理解生物系统复杂行为的合理性”这样一个极具挑战的问题。应用数学家林家翘先生提出“20世纪的应用数学聚焦于物理学问题，21世纪的应用数学数学应致力解决生物学问题”，预示了数学与生命科学交叉融合的重要性。在数理建模篇，将由国内一流的数学生物学团队介绍他们在这一领域的探索，侧重于肿瘤免疫相互作用的数学建模，尝试通过机理与数据驱动相结合的研究手段，采用微分方程组(随机或确定性)并结合随机模拟来描述肿瘤免疫响应的动力学演变过程。虚拟细胞在当前AI高歌猛进的时代背景下似乎成了时代的宠儿——2026年伊始，最小人造细胞JCVI-syn3A的数字克隆取得新的进展——虚拟细胞精确复现了细胞分裂动力学周期和关键事件。虚拟细胞是理解生命现象的前沿领域，被寄希望应用于药物研发和临床药理学领域。本次读书会邀请到了首届全球虚拟细胞大赛冠军团队百图生科技术副总监郭玉成博士，他将对该次突破性虚拟细胞建模的技术路线进行解读，郭玉成博士目前已经着手在实验室复现此次虚拟细胞的动力学过程。【工程技术篇】这一模块将从国药之光康方生物双抗类药物的研发实践开始，讨论免疫调节工具研发的工程实践，药物的临床验证和优化使用情况。最后聚焦到临床痛点，宿主治疗响应的评估与监测，提高药物有效率的联合治疗和系统管理策略。模块的设计初衷是希望通过系统回顾双特异性抗体的研发逻辑、PD-1抑制剂的临床药理、免疫紊乱的抗炎治疗、情绪应激与免疫应答之间的机制，结合几个具体的典型案例，来讨论：宿主免疫对治疗响应的监控与控制，如何优化肿瘤免疫联合治疗方案？进而在本模块跨学科讨论的基础上回归到第一性原理，探讨新生物视角下临床困境的出路和科学探索方向。【总结】由在肿瘤免疫学领域深耕20余年的张晓实教授主持讨论，主题是“提高肿瘤免疫治疗应答率的联合用药策略和系统管理框架”。时间信息22026年8月31日（周一）晚19:30-21:30，腾讯会议线上进行，感兴趣的朋友扫码报名加入免疫复杂性读书会后，可进入学员群进行交流。报名读书会：「免疫复杂性读书会：范式、理论与工具」，是一个以免疫现象为核心场景，以复杂科学为方法论，试图整合机制研究、数理建模、研发和临床实践问题来思考21世纪生命科学认知范式转型的跨学科研讨社群。讲者们来自各自领域的一线前沿，将基于自己长期的工作积淀与思考展开演讲，同时提供精要的参考文献。本读书会将围绕一个临床问题——如何优化以免疫治疗为中心的控瘤策略？——来展开讨论。试图以范式思考与理论建模视角，回归到第一性原理的起点，去重构认知框架，激发对话与洞见。发起人团队认为，将免疫系统视为动态复杂适应性网络，基于认知范式思考肿瘤免疫治疗的瓶颈——或能对当前免疫治疗的困境有所突破，构建出一套有效的联合治疗原则性框架，为临床实践提供指引。扫描海报中二维码报名参加读书会报名方式第一步：微信扫码填写报名信息。第二步：填写信息后，付费报名。如需用支付宝支付，请在PC端进入读书会页面报名支付：第三步：添加运营助理微信，拉入对应主题的读书会社区（微信群）。PS：我们鼓励围绕系统肿瘤免疫学、系统生物学、复杂网络与数学生物学及相关具体问题的深入探讨。为保证讨论质量，请避免发表脱离本期读书会主题、缺乏实证基础或过于空泛的哲学思辨类内容。若讨论内容明显偏离主题，经主持人提醒后仍未调整，为维护整体学习环境，我们将不得不将该成员请出讨论群，并根据其实际参与进度，对未参与部分按比例办理退费。感谢您的理解与配合，让我们共同营造一个专注、深入、有收获的共学空间。加入社区可享核心资源成为会员即可解锁完整学习生态，包括：线上实时问答、全部课程录播回看、独家资料共享、高质量社群交流、第一手信息同步，以及通过参与共创任务获取积分等权益。特色退费与激励机制我们提供以下两种途径，让您的投入获得实际回馈：任务达标退费路径认领并合格完成任意三期字幕任务，即可退还全额报名费，并额外获得集智专属周边奖励。运营成长激励路径合格完成一个字幕任务后，可申请成为运营助理。在读书会项目顺利结项后，将退还学费。表现优异者，还有机会获得额外的奖学金。

2026-08-31

·微信

柳叶刀·胃肠病学与肝病学 11卷 7-9期

THE LANCET Gastroenterology & Hepatology. Volume 11Number7 柳叶刀·胃肠病学与肝病学 11卷 7期 https://www.thelancet.com/journals/langas/issue/current Editorial（社论） 1 Rome V: refining the language of gut–brain disorders 罗马Ⅴ：完善肠–脑疾病的术语体系 The Lancet Gastroenterology & Hepatology The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p541 Comment（述评） 2 A changing HIV treatment landscape: what does lenacapavir mean for people living with HBV? HIV治疗格局之变：来那卡帕韦对HBV感染者意味着什么？ Philippa C Matthews,Marion Delphin,Motswedi Anderson,Joanna Redmond,Stuart Flanagan,Maryam Shahmanesh The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p542 3 Alaska Native peoples and colorectal cancer: opportunities for research and prevention 阿拉斯加原住民与结直肠癌：研究与预防的机遇 Diana Redwood,LaRita Laktonen-Ward,Elena Roik The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p544 4 Breaking the cycle: from documenting data scarcity to enabling global IBD research 打破循环：从记录数据匮乏到推动全球IBD研究 Mohammed Nabil Quraishi,Badr Al-Bawardy,Rupa Banerjee,Maiara Brusco De Freitas,David Epstein,Tine Jess The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p546 Correspondence（读者来信） 5 Cyclic exclusive enteral nutrition in paediatric Crohn's disease 儿童克罗恩病的周期性全肠内营养 Aaron S Bancil,Edward M Giles,Jessica Fitzpatrick The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p550 6 Cyclic exclusive enteral nutrition in paediatric Crohn's disease – Authors’ reply 儿童克罗恩病的周期性全肠内营养——作者回复 Bénédicte Pigneur,Frank M Ruemmele The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p550 7 Upfront medical or surgical treatment in Crohn's disease 克罗恩病的初始药物治疗还是手术治疗 Nurulamin M Noor,Phillip R Fleshner,Gil Y Melmed,Corey A Siegel The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p551 8 Upfront medical or surgical treatment in Crohn's disease – Authors’ reply 克罗恩病的初始药物治疗还是手术治疗——作者回复 Lotte Oldenburg,Anouck E G Haanappel,Geert R D’Haens,Willem A Bemelman The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p552 9 Cirrhotic cardiomyopathy and portal hypertension: addressing the full disease spectrum in heart–liver co-management 肝硬化心肌病与门静脉高压：在心–肝协同治疗中关注完整疾病谱 Madeleine Gill,Geoffrey W McCaughan,Anoop N Koshy,John F O’Sullivan,Avik Majumdar The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p553 Corrections（勘误） 10 Correction to Lancet Gastroenterol Hepatol 2026; 11: 355–66 勘误：柳叶刀·胃肠病学与肝病学 2026; 11: 355–66 The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：e9 11 Correction to Lancet Gastroenterol Hepatol 2026; 11: 557–69 勘误：柳叶刀·胃肠病学与肝病学 2026; 11: 557–69 The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：e9 News（新闻） 12 Digestive Disease Week 2026 2026年消化疾病周 Bethany Gomersall The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p555 In Focus（焦点） Theatre（剧场） 13 Wee, Poo, Snot: harnessing bodily functions to inspire budding scientists 尿液、粪便、鼻涕：利用身体功能激发未来科学家的兴趣 Peter Ranscombe The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p556 Articles（论著） 14 Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial 辅助放化疗与局部切除后完全全直肠系膜切除术治疗早期直肠癌（TESAR）：一项多中心、随机、对照、3期、非劣效性试验 Laura R Moolenaar,Mahsoem Ali,Theo J Aufenacker,Geerard L Beets,Robbert J I Bosker,Tineke E Buffart,Jacobus WA Burger,Evelien Dekker,Quentin Denost,Pascal G Doornebosch,Peter van Duijvendijk,Hans F J Fabry,Elisabeth D Geijsen,Michael F Gerhards,Wilhelmina M U van Grevenstein,Brechtje A Grotenhuis,Christiaan Hoff,Jeroen W A Leijtens,Koen C M J Peeters,Apollo Pronk,George P van der Schelling,Colin Sietses,Anke B Smits,Boudewijn R Toorenvliet,Anthony W H van de Ven,Emiel G G Verdaasdonk,Ronald J C L M Vuylsteke,Henderik L van Westreenen,Johannes H W de Wilt,David D E Zimmerman,Marilyne M Lange,Nicole C T van Grieken,Barbara A J Bastiaansen,Roel Hompes,Corrie A Marijnen,Marcel G W Dijkgraaf,Leon M G Moons,Pieter J Tanis,Chris Cunningham,J B Tuynmanon behalf of the TESAR Study Group The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p557 15 Effect of one or two cycles of dual immunotherapy with nivolumab and ipilimumab in patients with mismatch repair-deficient rectal cancer (RESET-R): interim results from a multicentre, single-arm, phase 2 trial 纳武利尤单抗联合伊匹木单抗双免疫治疗一或两个周期对错配修复缺陷型直肠癌患者的疗效（RESET-R）：一项多中心、单臂、2期试验的中期结果 Line Schmidt Tarpgaard,Laurids Østergaard Poulsen,Ismail Gögenur,Tobias Freyberg Justesen,Søren Rafael Rafaelsen,Nadia Øgaard,Christina Demuth,Claus Lindbjerg Andersen,Lise Ventzel,Pernille Øhlenschläger Larsen,Anne Ramlov,Ken Ljungmann,Michael Bødker Lauritzen,Laura Vittrup Diness,Jakob Lykke,Vinicius Araújo Barbosa de Lima,Søren Kjær,Søren Salomon,Per Vadgaard Andersen,Per Pfeiffer The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p570 16 The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729–001): a phase 1a/b trial 小干扰RNA imdusiran（药物名称）在健康随机个体及慢性乙型肝炎非随机个体中单次及多次给药的研究（AB-729–001）：一项1a/b期试验 Man-Fung Yuen,Edward Gane,Jacinta A Holmes,Simone I Strasser,Apinya Leerapun,Wattana Sukeepaisarnjaroen,Pisit Tangkijvanich,Elina Berliba,Alina Jucov,Yoon Jun Kim,Young-Suk Lim,Emily P Thi,Timothy Eley,Kevin R Gray,Elina Medvedeva,Varun Sharma,Christine Espiritu,Sharie C Ganchua,Bhavna S Paratala,Christina Iott,Heather Sevinsky,Tiffany Fortney,Mark Anderson,Gavin A Cloherty,Michael J Sofia,Ganapati Reddy Pamulapati,Amy C H Lee,Gastón Picchio,Karen D Sims The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p579 17 Intestinal ultrasound to detect postoperative recurrence in patients with Crohn's disease: an international, multidisciplinary, RAND/UCLA appropriateness method study 肠道超声检测克罗恩病术后复发：一项国际多学科RAND/UCLA适宜性方法研究 Christopher Ma,Siwar Albashir,Mariangela Allocca,Anthony de Buck van Overstraeten,Paulo G Kotze,Cathy Lu,Christian Maaser,Giovanni Maconi,Remo Panaccione,Miguel Regueiro,Jordi Rimola,Antonino Spinelli,Stuart A Taylor,Rune Wilkens,Willem Bemelman,Noa Krugliak Cleveland,Krisztina B Gecse,Susan Archer,Soushyant Kiarasi,Linda J Cornfield,Kerri L Novak The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p602 Review（综述） 18 The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus 非肝硬化代谢功能障碍相关脂肪性肝炎的药物治疗：英国专家共识 Jeremy F Cobbold,Hamish Miller,Kate Hallsworth,Pinelopi Manousou,Thomas Marjot,Michael E D Allison,Quentin M Anstee,Matthew J Armstrong,Leah Avery,Vian Azzu,Paul N Brennan,Christopher D Byrne,Tessa M Cacciottolo,Lynsey Corless,Daniel Forton,Timothy Hardy,Vanessa Hebditch,Helen Jarvis,Wenhao Li,Dina Mansour,Stuart McPherson,Yensiew Miao,Joanne Morling,Ashis Mukhopadhya,Benjamin Mullish,Richard Parker,Imran Patanwala,Jay Patel,Michael Pavlides,Tina Reinson,Ian A Rowe,Francesca Saffioti,Faisal Shaikh,Ankur Srivastava,Nwe Ni Than,Emmanuel Tsochatzis,Edvard Volcek,Jeremy W Tomlinson,William Alazawi The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p616 19 Management of colorectal cancer in older adults: an expert panel recommendation to guide daily clinical practice 老年结直肠癌的治疗：指导日常临床实践的专家组建议 Gabor Liposits,Thierry André,Thomas Aparicio,Isacco Montroni,Julien Taieb,Claire Gallois,Eric Van Cutsem,Michel Ducreux,Per Pfeiffer,Sara Lonardi,Geerard L Beets,Karin Haustermans,Naureen Starling,Gerald W Prager,Gunnar Folprecht,Demetris Papamichael The Lancet Gastroenterology & Hepatology. Jul 2026, Vol 11(7)：p627 THE LANCET Gastroenterology & Hepatology. Volume 11Number 8 柳叶刀·胃肠病学与肝病学 11卷 8期 https://www.thelancet.com/journals/langas/issue/current Editorial（社论） 1 Drugging the undruggable in pancreatic cancer 攻克胰腺癌中“不可成药”靶点的药物研发 The Lancet Gastroenterology & Hepatology The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p645 Comment（述评） 2 Effect of repeated elastography measurements in LiverScreen 肝脏筛查项目中重复弹性检测的临床价值 Hannes Hagström,Ying Shang The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p646 3 Metabolic syndrome myopathy: defining an emerging clinical entity in patients with MASLD 代谢综合征肌病：代谢相关脂肪性肝病患者一类新兴临床疾病的确立 Melinda Wang,Jennifer C Lai The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p647 4 All in her head: dismantling medical misogyny in disorders of gut–brain interaction 一切皆源于主观臆症：破除肠脑互动疾病诊疗中的医学厌女偏见 Tiffany H Taft,Tina Aswani-Omprakash,Johannah Ruddy The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p650 Correspondence（读者来信） 5 COLOR III: widespread TaTME dissemination demands a LAPCO-equivalent framework COLOR III研究：经肛全直肠系膜切除术广泛推广亟需建立等同腹腔镜结直肠手术协作组的规范体系 Shazad Q Ashraf,Andrew D Beggs The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p653 6 The spectrum of steatotic liver disease in the USA 美国脂肪性肝病疾病谱 Kartik Jaidka,Naveen Bhagat,Arka De,Ajay Duseja The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p653 7 The spectrum of steatotic liver disease in the USA 美国脂肪性肝病疾病谱 Hans Scherübl The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p654 8 The spectrum of steatotic liver disease in the USA – Authors’ reply 《美国脂肪性肝病疾病谱》——作者答复 James M Paik,Zobair M Younossi The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p655 9 Lessons from a ransomware crisis and its effect on adult liver transplant services 勒索软件网络危机及其对成人肝移植诊疗服务的影响与启示 Abdul Rahman Hakeem,Karen Mercer,Bu Hayee,Oliver Long,Abid Suddle,Wayel Jassem,Parthi Srinivasan,Krishna Menon,Anneliese Rigby,Miriam Cortes-Cerisuelo,Varuna Aluvihare The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p655 Corrections（勘误） 10 Correction to Lancet Gastroenterol Hepatol 2025; 10: 998–1012 《柳叶刀-胃肠病学与肝病学》2025年第10卷998–1012页文章勘误 The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：e10 11 Correction to Lancet Gastroenterol Hepatol 2026; 11: 546–49 《柳叶刀-胃肠病学与肝病学》2026年第11卷546–549页文章勘误 The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：e10 News（新闻资讯） 12 EASL Congress 2026 2026年欧洲肝脏研究协会年会 Rob Brierley The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p658 13 Research in Brief 研究简讯 Holly Baker The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p659 Articles（论著） 14 HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype–phenotype association study 炎症性肠病患者HLA-DRB1*01:03基因型：基因型-表型关联研究 Qian Zhang,Eathar Shakweh,Mohmmed Tauseef Sharip,Benjamin Zare,Christopher Roberts,Nicola J Wyatt,Jennifer Clough,Claire Bewshea,Omar El Garwany,Robert Lees,Saima Mukhtar,Hameed Rehman,Hollie Thistle,Robert Mulligan,Melanie Taylor,Parizade Raymode,Benjamin Hamilton,Nurulamin M Noor,Francesco Morda,Madeleine Taylor,Mina Gyanwali,Ogwa Tobi,Stefanos Kateroglou,Sean Von Hagt,UK IBD Genetics Consortium,NIHR IBD BioResource,Shaji Sebastian,Ailsa Hart,Laura Keylock,Laetitia Pele,Charlie W Lees,Tim Raine,Christopher A Lamb,Carl A Anderson,Tariq Ahmad,Holm Uhlig,Miles Parkes,Laura Fachal,Nicholas A Kennedy,James C Lee The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p660 15 Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial 度普利尤单抗对比安慰剂治疗成人及青少年嗜酸性粒细胞性胃炎（DEGAS研究）：一项Ⅱ期、双盲、安慰剂对照、多中心随机对照临床试验 Nirmala P Gonsalves,Evan S Dellon,Kara L Kliewer,Tetsuo Shoda,Regina Yearout,Seema S Aceves,Nicoleta C Arva,John A Besse,Julie M Caldwell,Mirna Chehade,Amaziah Coleman,Margaret H Collins,Sara Anvari,Gary W Falk,Sandeep K Gupta,Girish Hiremath,David A Katzka,Paneez Khoury,John Leung,Calies Menard-Katcher,Paul Menard-Katcher,Kathryn A Peterson,Maria A Pletneva,Amanda K Rudman Spergel,Jonathan M Spergel,Tatyana Vaysman,Joshua B Wechsler,Benjamin L Wright,Guang-Yu Yang,Xue Zhang,Meijian Zhou,Ashish Bansal,Bram P Raphael,Amr Radwan,Jennifer Maloney,Antonio Martin,Yamo Deniz,Glenn T Furuta,Lisa J Martin,Marc E Rothenbergfor The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Investigators The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p672 16 Liver stiffness dynamics in European populations (LiverScreen): a longitudinal, multicentre, prospective, population-based cohort study 欧洲人群肝脏硬度动态变化研究（肝脏筛查项目）：一项基于人群、多中心、前瞻性纵向队列研究 Jesse Pustjens,Katrine Tholstrup Bech,Guillem Pera,Laurens A van Kleef,Helle Lindholm Schnefeld,Robert J de Knegt,Sarwa Darwish Murad,Harry L A Janssen,Peter Andersen,Johanne Kragh Hansen,Llorenç Caballeria,Carla Chacon,Ingrid Arteaga,Pere Toran,Anita Arslanow,Anna Soria,Marta Cervera,Aleksander Krag,Isabel Graupera,Pere Ginès,Willem Pieter Brouwer,Maja Thieleon behalf of the LiverScreen Consortium Investigators The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p689 17 Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial 阿替利珠单抗联合贝伐珠单抗基础上加用伊匹木单抗治疗晚期肝细胞癌（PRODIGE 81-FFCD 2101-TRIPLET HCC研究）：一项多中心、开放标签Ⅱ/Ⅲ期随机临床试验Ⅱ期研究结果 Philippe Merle,Jean-Frederic Blanc,Karine Le Malicot,Jean-Marie Peron,Vincent Bourgeois,Mohamed Bouattour,Yann Touchefeu,Carole Vitellius,Faiza Khemissa Akouz,Alexandra Heurgué,Paul Girot,Eric Assenat,Eric Nguyen-Khac,Jean-Pierre Bronowicki,Juliette Viaud,Meher Ben Abdelghani,Sylvain Manfredi,Julien Edeline,Jean-Marc Phelipfor the TRIPLET-HCC study investigators The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p700 Viewpoint（观点） 18 Breaking the therapeutic ceiling in inflammatory bowel disease: myth or reality? 突破炎症性肠病治疗瓶颈：空想还是现实？ Virginia Solitano,Vipul Jairath,Fernando Magro,Alessandro Armuzzi,Laurent Peyrin-Biroulet,Silvio Danese The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p713 19 Balancing benefit and burden: rethinking post-polypectomy colonoscopy surveillance strategies 权衡获益与医疗负担：重新思考息肉切除术后结肠镜随访监测策略 Joep E G IJspeert,Michael Bretthauer,Rodrigo Jover,Evelien Dekkeron behalf of the Dutch colonoscopy surveillance working group The Lancet Gastroenterology & Hepatology. Aug 2026, Vol 11(8)：p720 THE LANCET Gastroenterology & Hepatology. Volume 11Number 9 柳叶刀·胃肠病学与肝病学 11卷 9期 https://www.thelancet.com/journals/langas/issue/current Editorial（社论） 1 A decade in gastroenterology and hepatology 胃肠病学与肝病学十年回顾 The Lancet Gastroenterology & Hepatology The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p727 Comment（评述） 2 Low‑dose aspirin: effective cancer chemoprevention in Lynch syndrome 低剂量阿司匹林：林奇综合征有效的癌症化学预防方案 Kevin J Monahan The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p728 3 RELIEVE UCCD: one pathway, two diseases, and a glimpse into the future of IBD trial design RELIEVE‑UCCD研究：同一条通路、两类疾病，窥探炎症性肠病临床试验设计的未来方向 Bram Verstockt The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p729 4 Combination therapy in metabolic dysfunction‑associated steatohepatitis 代谢功能障碍相关脂肪性肝炎的联合治疗 Oren Shibolet,Helena Katchman The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p732 5 The central role of primary care in liver health 基层医疗在肝脏健康管理中的核心作用 Rob Brierley,Hugh Thomas The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p733 6 A decade in inflammatory bowel disease: progress, plateaus, and perspectives 炎症性肠病十年发展：进展、瓶颈与展望 Britta Siegmund The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p735 7 A decade of transformation in MASLD: from nomenclature to novel therapies 代谢功能障碍相关脂肪性肝病十年变革：从命名更新到新型疗法 Jörn M Schattenberg,Mazen Noureddin The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p737 8 Dietary management of gastrointestinal disease: progress over the last decade and opportunities for the next 胃肠道疾病的膳食干预：近十年进展与未来机遇 Kevin Whelan,Heidi M Staudacher The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p738 9 The decade that changed hepatocellular carcinoma: shaping a new treatment paradigm 改写肝细胞癌诊疗格局的十年：构建全新治疗模式 Antonio D’Alessio,Antonella Cammarota,Stephen L Chan,Lorenza Rimassa The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p741 10 Ten years of advances in disorders of gut–brain interaction 肠‑脑互动相关疾病十年研究进展 Alexander C Ford,Nicholas J Talley The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p743 11 Progress and prospects in viral hepatitis elimination 病毒性肝炎消除工作的进展与前景 C Wendy Spearman,Mark W Sonderup The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p745 12 A decade of progress in cholestatic liver diseases: navigating a new era 胆汁淤积性肝病十年进展：迈入全新发展阶段 Vincenzo Ronca,Maria Buzias,Ana Lleo The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p748 13 Translating the gut microbiome: where are we? 肠道微生物组的临床转化：当下发展现状 Jeroen Raes The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p750 14 A decade of artificial intelligence in endoscopy: from proof of concept to clinical reality 人工智能内镜应用十年：从概念验证走向临床落地 Masashi Misawa,Yuichi Mori The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p752 15 A decade of diversity, equity, and inclusion in gastroenterology and hepatology: a US perspective 胃肠肝病领域多元、公平与包容建设十年——美国视角 Pascale M White,Nikki Duong,Laura E Targownik,Sophie Balzora The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p754 Correspondence（通信） 16 Therapeutic drift or formulation drift: avoiding misconceptions about rifaximin and antimicrobial resistance in cirrhosis 药效偏移还是制剂差异：厘清肝硬化患者利福昔明与抗菌耐药性的认知误区 Carmelo Scarpignato,Manuel Romero‑Gómez The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p757 17 Therapeutic drift or formulation drift: avoiding misconceptions about rifaximin and antimicrobial resistance in cirrhosis –Authors' reply 药效偏移还是制剂差异：厘清肝硬化患者利福昔明与抗菌耐药性的认知误区——作者回复 Rajiv Jalan,Vishal C Patel,Saeed Shoaie The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p758 18 Ethnicity, diversity, and inclusion in gastroenterology: from representation to system performance 胃肠病学领域种族、多元与包容建设：从人员覆盖到体系效能 Ajay M Verma,Debbie L Shawcross,Neeraj Bhala The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p758 Articles（论著） 19 Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double‑blind, non‑inferiority trial 阿司匹林用于林奇综合征人群癌症预防：CaPP3多中心随机双盲非劣效性试验初步结果 John Burn,Gillian M Borthwick,Faye Elliott,Finlay Macrae,Kai Ren Ong,Alison C Kraus,Nadir Arber,Jukka‑Pekka Mecklin,Angel Alonso,Emma R Woodward,D Gareth Evans,Alex Murray,Katie Snape,Ruth E Cleaver,Adam Shaw,Huw J W Thomas,Ajith V Kumar,Dorothy Halliday,Lucy E Side,Rachel E Harrison,Rosemarie Davidson,Ruth Armstrong,Jackie Cook,Rachel Hart,Patrick J Morrison,Julian G Barwell,Alan Donaldson,Zoe Kemp,Jennie Murray,Zosia Miedzybrodzka,Caroline Pottinger,Jonathan Berg,Richard Gallon,D Timothy Bishopon behalf of the CaPP3 co‑investigators The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p760 20 Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo‑controlled trial Duvakitug治疗溃疡性结肠炎的疗效与安全性（RELIEVE‑UCCD）：2b期随机安慰剂对照试验 Walter Reinisch,David Stepek,Radoslaw Kempinski,Silvio Danese,Bruce E Sands,Bogdan Ratiu‑Duma,Rajendra Singh,Phillip Levine,Hadas Barkay,Nicholas Gross,Ken Abrams,Vipul Jairath The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p775 21 Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo‑controlled trial Duvakitug治疗克罗恩病的疗效与安全性（RELIEVE‑UCCD）：2b期随机安慰剂对照试验 Vipul Jairath,Jaroslaw Kierkuś,George Aaron Duvall,Silvio Danese,Bruce E Sands,Bogdan Ratiu‑Duma,Rajendra Singh,Phillip Levine,Hadas Barkay,Nicholas Gross,Ken Abrams,Walter Reinisch The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p786 22 Efficacy and safety of zalfermin co‑administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction‑associated steatohepatitis: a phase 2, dose‑ranging, double‑blind, randomised controlled trial 扎弗明联合司美格鲁肽治疗代谢相关脂肪性肝炎所致肝纤维化与肝硬化受试者的疗效及安全性：2期剂量探索双盲随机对照试验 Rohit Loomba,Jacob George,Laurent Castera,Sven Francque,Eric Lawitz,Ahsan Shoeb,Jesper Ole Clausen,Birgitte Andersen,Anna Bille Larsen,Lise Lotte Gluud The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p797 23 The Rome V criteria for the diagnosis of irritable bowel syndrome in secondary care: a diagnostic accuracy study 二级医疗机构中罗马V标准诊断肠易激综合征的诊断准确度研究 Kyle Staller,Vivek C Goodory,Mais Khasawneh,Christopher J Black,Alexander C Ford The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p812 The Lancet Gastroenterology & Hepatology Commission（《柳叶刀‑胃肠病学和肝病学》专题委员会报告） 24 The role of primary care in response to the global liver disease syndemic: a Lancet Gastroenterology & Hepatology Commission 基层医疗应对全球肝病共病流行的作用——《柳叶刀‑胃肠病学和肝病学》专题委员会报告 Helen Jarvis,Paul N Brennan,Teresa Casanovas,Kelly Casler,Monica Desai,Philip H Evans,John F Dillon,Ignazio Grattagliano,Kate Hallsworth,Vanessa Hebditch,Sema Mandal,Alisa E Pedrana,Jen‑Kuei Peng,Andrew D Schreiner,Abdel‑Aziz Shaheen,Maja Thiele,Patricia C Valery,Julia Verne,Shlomo Vinker,David Whiteley,Martin C S Wong,Shira Zelber‑Sagi The Lancet Gastroenterology & Hepatology. Num 2026, Vol 11(9)：p821

100 项与伊匹木单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04603	伊匹木单抗	L01XC11	DB06186

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
微卫星高度不稳定性直肠癌	日本	Bristol-Myers Squibb KK	2025-08-25
PD-L1阳性非小细胞肺癌	中国	Bristol-Myers Squibb Pharma EEIG	2025-07-22
转移性肝细胞癌	澳大利亚	Bristol-Myers Squibb Australia Pty Ltd.	2025-06-27
晚期肝细胞癌	欧盟	Bristol Myers Squibb Co.	2025-03-08
晚期肝细胞癌	冰岛	Bristol Myers Squibb Co.	2025-03-08
晚期肝细胞癌	列支敦士登	Bristol Myers Squibb Co.	2025-03-08
晚期肝细胞癌	挪威	Bristol Myers Squibb Co.	2025-03-08
不可切除的肝细胞癌	欧盟	Bristol Myers Squibb Co.	2025-03-08
不可切除的肝细胞癌	冰岛	Bristol Myers Squibb Co.	2025-03-08
不可切除的肝细胞癌	列支敦士登	Bristol Myers Squibb Co.	2025-03-08
不可切除的肝细胞癌	挪威	Bristol Myers Squibb Co.	2025-03-08
错配修复缺陷或微高卫星不稳定性结肠癌	欧盟	Bristol-Myers Squibb Pharma EEIG	2025-01-13
错配修复缺陷或微高卫星不稳定性结肠癌	冰岛	Bristol-Myers Squibb Pharma EEIG	2025-01-13
错配修复缺陷或微高卫星不稳定性结肠癌	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2025-01-13
错配修复缺陷或微高卫星不稳定性结肠癌	挪威	Bristol-Myers Squibb Pharma EEIG	2025-01-13
不能切除的食管鳞状细胞癌	美国	Bristol Myers Squibb Co.	2022-05-27
食管癌	日本	Bristol-Myers Squibb KK	2022-05-26
肝细胞癌	美国	Bristol Myers Squibb Co.	2020-03-10
皮肤黑色素瘤	美国	Bristol Myers Squibb Co.	2018-07-10
结直肠癌	美国	Bristol Myers Squibb Co.	2018-04-16

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膀胱癌	临床3期	美国	Ono Pharmaceutical Co., Ltd.	2022-01-30
HER2阴性胃癌	临床3期	日本	Ono Pharmaceutical Co., Ltd.	2021-11-05
HER2阴性胃癌	临床3期	韩国	Ono Pharmaceutical Co., Ltd.	2021-11-05
HER2阴性胃癌	临床3期	中国台湾	Ono Pharmaceutical Co., Ltd.	2021-11-05
胶质母细胞瘤	临床3期	美国	National Cancer Institute	2020-09-01
神经胶质肉瘤	临床3期	美国	National Cancer Institute	2020-09-01
非小细胞肺癌 III期	临床3期	荷兰	Bristol Myers Squibb Co.	2019-12-16
局部晚期非小细胞肺癌	临床3期	美国	Bristol Myers Squibb Co.	2019-10-08
局部晚期非小细胞肺癌	临床3期	中国	Bristol Myers Squibb Co.	2019-10-08
局部晚期非小细胞肺癌	临床3期	日本	Bristol Myers Squibb Co.	2019-10-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03274258 (CTgov)	临床2期	肾髓样癌	10	Ipilimumab+Nivolumab	築糧醖積製繭窪積蓋襯 = 夢艱糧顧繭膚窪餘蓋鑰遞鑰夢艱齋願衊餘醖艱 (網鑰膚襯鹹築艱製夢顧, 範觸顧製範襯鹽醖觸齋 ~ 選鬱網鏇襯鬱醖觸淵繭) 更多	-	2026-08-20
NCT05665348 (PRODIGE 81-FFCD 2101-TRIPLET HCC, Pubmed \| Lancet Gastroenterol Hepatol)	临床2/3期	晚期肝细胞癌一线	226	Atezolizumab + Bevacizumab + Ipilimumab	衊淵蓋蓋簾繭襯襯淵鏇(糧淵鬱廠餘餘壓範餘範) = 3% of patients in the atezolizumab plus bevacizumab group experienced acute renal failure 獵構壓鬱廠蓋餘夢糧廠 (鏇觸餘蓋簾製獵繭壓窪 ) 更多	不佳	2026-08-01
				Atezolizumab + Bevacizumab
NCT04039607 (CheckMate 9DW, ESMO_GI2026 \| ESMO_GCC2026)	临床3期	不可切除的肝细胞癌一线	208	Nivolumab (NIVO) + ipilimumab (IPI)	觸積顧廠繭製鑰蓋構顧(襯廠選窪蓋繭夢憲網製) = 繭選鑰積構顧顧獵壓鏇鑰衊蓋簾鹽獵簾衊醖鹽 (蓋繭夢齋製獵製鹽觸壓, 4.9 ~ NR) 更多	积极	2026-07-02
				Lenvatinib (LEN) or Sorafenib (SOR)	觸積顧廠繭製鑰蓋構顧(襯鏇選願憲壓淵襯簾觸) = 糧憲壓築艱遞齋鬱鬱齋繭夢鏇糧繭壓鏇選獵製 (鑰窪窪壓夢鏇簾鹽鑰繭, 13.9 ~ 24.7) 更多
ESMO_GI2026 \| ESMO_GCC2026	N/A	PD-L1阳性食管鳞状细胞癌	26	Nivolumab + ipilimumab	艱鑰淵願廠蓋選製淵鬱(壓製壓鹽鹽範夢壓網願) = 構觸夢窪製膚選選齋壓範製繭廠餘觸壓齋鬱網 (憲淵願網鏇蓋獵夢簾鏇 ) 更多	不佳	2026-07-02
NCT03682276 (PRIME-HCC, CTgov)	临床1/2期	肝细胞癌	33	Ipilimumab+Nivolumab	鏇壓顧觸壓簾繭製壓積 = 廠淵夢餘選淵鹹鑰鏇範壓積構壓築製壓壓醖醖 (選窪餘築遞鹽簾齋窪壓, 簾膚鏇網獵築窪遞鑰積 ~ 鏇觸衊鑰範簾膚觸獵積) 更多	-	2026-06-29
NCT03958383 (CTgov)	临床1/2期	黑色素瘤	8	hu14.18-IL2 fusion protein (Phase IA)	製鹹壓廠網鏇築膚鏇鏇 = 糧獵鏇築糧遞襯淵積廠齋鹽網壓壓獵製淵鏇繭 (製膚糧淵壓糧淵遞觸窪, 遞醖獵簾膚憲蓋廠夢獵 ~ 廠鹹構餘製鹹齋網獵鏇) 更多	-	2026-06-03
				hu14.18-IL2 (Phase IB)	製鹹壓廠網鏇築膚鏇鏇 = 繭壓遞鏇構繭製觸鏇願齋鹽網壓壓獵製淵鏇繭 (製膚糧淵壓糧淵遞觸窪, 顧範淵繭膚鹹鑰築繭餘 ~ 觸壓鹽蓋範觸鏇範壓憲) 更多
NCT06712927 (RELATIVITY-048, ASCO2026)	临床2期	黑色素瘤	60	Nivolumab 480mg + Relatlimab 160mg IV Q4W + Ipilimumab 1mg/kg IV Q8W	鬱鬱鹹選蓋願積網壓願(築簾築鹹蓋鹹膚範網獵) = 憲齋範壓夢淵壓繭鬱鏇網艱遞鹹鏇襯遞鏇鹽網 (膚窪繭廠壓簾淵顧糧糧 ) 更多	积极	2026-05-29
				Nivolumab 480mg + Relatlimab 160mg IV Q4W + Ipilimumab 1mg/kg IV Q8W	鬱鬱鹹選蓋願積網壓願(築簾築鹹蓋鹹膚範網獵) = 築醖網製憲築網壓襯壓網艱遞鹹鏇襯遞鏇鹽網 (膚窪繭廠壓簾淵顧糧糧 )
ASCO2026	N/A	黑色素瘤 2-hydroxybutyric acid	36	ipilimumab-nivolumab	築齋膚範鑰鏇膚鑰選選(糧構網衊憲齋鹽鏇築糧) = 繭蓋鹽獵鹹簾製憲衊範觸製蓋範鑰淵鬱製觸範 (簾網廠憲顧膚壓醖繭齋 ) 更多	积极	2026-05-29
ASCO2026	N/A	转移性非小细胞肺癌一线	344	Ipilimumab and Nivolumab	齋夢齋壓壓鹽夢膚艱遞(鏇繭餘鹹鹽蓋餘醖襯鏇) = 選窪繭鏇構願艱簾選廠膚簾簾繭鏇鹽廠網鑰網 (製繭蓋願鹹網鏇襯選糧 ) 更多	积极	2026-05-29
				Chemotherapy+PD-1/PD-L1 inhibitor	齋夢齋壓壓鹽夢膚艱遞(鏇繭餘鹹鹽蓋餘醖襯鏇) = 廠蓋艱構蓋願鬱顧餘壓膚簾簾繭鏇鹽廠網鑰網 (製繭蓋願鹹網鏇襯選糧 ) 更多
NCT02866383 (CheckPAC, ASCO2026)	临床2期	胆道癌 NordicPRO-C3 \| NordicC4G	61	nivolumab + nivolumab	鹹選廠製築鏇繭窪鏇鹽(窪積遞獵壓範夢繭廠獵) = 鑰鑰觸餘繭範鹹繭齋鑰製膚廠淵夢鹽壓築範網 (餘遞襯壓衊餘淵鹹膚獵 ) 更多	积极	2026-05-29
				nivolumabipilimumab + nivolumabipilimumab + nivolumabipilimumab	壓鹹鏇簾艱餘願鬱糧構(構糧憲鏇夢範獵醖淵願) = 夢壓窪鹽襯衊淵衊糧願願顧鹽醖觸範網壓膚壓 (鑰醖憲醖衊鹽壓獵艱餘 )